FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million glob...
Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (&...
Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for ...
BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dis...
Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with exte...
- Cipla USA Inc. the wholly owned subsidiary of Cipla Limited announced final approval from the U.S. Food and Drug Administration (USFDA) for its Abbrevi...
OneCyte, a leader in high-throughput single-cell analysis and cell line development technologies, and Kemp Proteins, a pioneer in protein engineering and...
A pivotal step in PharmaEssentia's dual-site U.S.-Taiwan manufacturing strategy, with 2027 operations in sight PharmaEssentia Corporation (TWS...
Government investment will accelerate clinical development and strengthen Aspect’s advanced biomanufacturing capabilities for its bioengineered c...
The partnership pairs Pillar's portfolio of oncoReveal® kitted NGS panels with CellCarta's global laboratory network and biomarker expertise to reduc...
Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-dr...
Thermo Fisher Scientific Inc., the world leader in serving science, announced the global launch of the Gibco™ CTS™ Compleo™ Fill ...
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders Centessa’s OX2R agonist pip...
Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic cardiomyopath...
© 2026 Biopharma Boardroom. All Rights Reserved.
